Portal de Periódicos da CAPES

Comments on the 2017 ESC/EACTS Guidelines for the Management of Valvular Heart Disease

2018; Elsevier BV; Volume: 71; Issue: 2 Linguagem: Inglês

10.1016/j.rec.2017.11.027

1885-5857

Arturo Evangelista, José Alberto San Román, Francisco Calvo, Ariana González, Juan José Gómez‐Doblas, Ana Revilla, Juan Antonio Castillo, Carlos González, Juan José Gómez‐Doblas, Teresa López‐Fernández, Manuel Barreiro‐Pérez, María J. Oliva, Laura Galián-Gay, Ana Serrador, Pilar Jiménez‐Quevedo, Manuel Pan, Miguel Ángel Arnau Vives, Javier López, Xavier Pérez, José Alberto San Román, Fernándo Alfonso, Arturo Evangelista, Ignacio Ferreira‐González, Manuel F. Jiménez‐Navarro, Francisco Marı́n, Leopoldo Pérez de Isla, Luis Rodrı́guez Padial, Pedro L. Sánchez, Alessandro Sionís, Rafael Vázquez,

Cardiac Valve Diseases and Treatments

Aortic valve disease is a common condition whose prevalence is increasing, especially in Western countries. Two main families of cardiac prostheses are available: mechanical and biological prostheses. Nevertheless, the use of mechanical surgical valves has declined significantly over time in favor of bioprosthetic surgical valves even among middle-aged patients. The dominance of bioprosthetic valves was enhanced further with the introduction of transcatheter aortic valves. However, some concerns have arisen in recent years about clinical and subclinical leaflet thrombosis of both surgical and transcatheter bioprostheses. This manuscript aims to discuss the current evidence relating to the incidence, pathophysiology, clinical implications, and management strategies of biological valve leaflet thrombosis.